PADCEV plus Keytruda reduces bladder cancer recurrence risk by 47%
Go back to PADCEV plus Keytruda reduces bladder cancer recurrence risk by 47%| Astellas Pharma Inc Unsponsored ADR (AMEX: ALPMY) | Delayed: 13.16 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $13.16 | 52 Week High | $19.40 | |||
| Open | $13.16 | 52 Week Low | $12.50 | |||
| Day High | $13.16 | P/E | N/A | |||
| Day Low | $13.16 | EPS | $0.00 | |||
| Volume | 37,000 | |||||
| Pfizer Inc. (NYSE: PFE) | Delayed: 24.72 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $24.72 | 52 Week High | $37.39 | |||
| Open | $24.72 | 52 Week Low | $28.25 | |||
| Day High | $24.72 | P/E | 14.98 | |||
| Day Low | $24.72 | EPS | $1.65 | |||
| Volume | 180,353 | |||||
